<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23431">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01979913</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-260213</org_study_id>
    <nct_id>NCT01979913</nct_id>
  </id_info>
  <brief_title>An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More</brief_title>
  <official_title>An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Anton Hommer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ordination Dr. Hommer</source>
  <oversight_info>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased intraocular pressure (IOP) has been identified as the most important risk factor
      for the development and the progression of glaucoma. Data from large interventional studies
      have shown that a decrease of IOP is associated with a reduced risk of progression of the
      disease. This underlines the importance of a potent and save IOP lowering therapy. The
      introduction of preservative free tafluprost offers a new treatment possibility using a
      potent topical prostaglandin analogue without the disadvantages of a co-administered
      preservative. The current study seeks to investigate the effect of an 8 week therapy with
      preservative free tafluprost on intraocular pressure in patients with ocular hypertension or
      primary open angle glaucoma having an IOP of 30 mmHg or more.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intraocular pressure will be measured at baseline, after 4 weeks and after 8 weeks at 8:00 am and 6:00 pm on each study day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with POAG or OHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with primary open angle glaucoma or ocular hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis</intervention_name>
    <arm_group_label>Patients with POAG or OHT</arm_group_label>
    <other_name>Tafluprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years

          -  Diagnosed primary open angle glaucoma and an IOP of 30mmHg or more in at least 1 eye
             at visit 1 at 8 am

          -  Patients with ocular hypertension as defined as an IOP of 30mmHg or more and normal
             findings in the visual field and the optic nerve head

        Exclusion Criteria:

          -  Participation in a clinical trial in the 3 weeks before the screening visit

          -  Severe visual field loss as defined as an MD of -15 or worse

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Presence or history of a severe medical condition that will interfere with the study
             aim as judged by the clinical investigator

          -  Presence or history of a severe ocular condition that will interfere with the study
             aim as judged by the clinical investigator

          -  Wearing of contact lenses

          -  Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except
             glaucoma medication or topical lubricants

          -  Ocular infection

          -  Ocular surgery in the 6 months preceding the study

          -  Pregnancy, planned pregnancy or lactating

          -  Contraindication against the use of topical prostaglandin therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anton Hommer, MD</last_name>
    <phone>+43 1 40 83 47</phone>
    <phone_ext>7</phone_ext>
    <email>a.hommer@aon.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ordination Dr. Hommer</name>
      <address>
        <city>Vienna</city>
        <zip>1080</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Hommer, MD</last_name>
      <phone>+43 1 40 83 47</phone>
      <phone_ext>7</phone_ext>
      <email>a.hommer@aon.at</email>
    </contact>
    <investigator>
      <last_name>Anton Hommer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ordination Dr. Hommer</investigator_affiliation>
    <investigator_full_name>Dr. Anton Hommer</investigator_full_name>
    <investigator_title>Dr. med. univ.</investigator_title>
  </responsible_party>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Tafluprost</keyword>
  <keyword>Saflutan</keyword>
  <keyword>Intraocular pressure</keyword>
  <keyword>Preservative free</keyword>
  <keyword>Single dose unit</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
